StockData
OptimizeRx Corp logo

OptimizeRx Corp (OPRX) stock

OPRXNasdaqServices-Business Services, NECFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 10/3030% below fair value
$6.94+0.30 (+4.52%)

Close on Nov 17, 2026Market cap $130.72MP/E 28.9Yield –

OptimizeRx r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was $0. The highest annual figure on record is $1.60M in fiscal 2019.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$0–
FY2024Dec 31, 2024$0–
FY2020Dec 31, 2020$0-100.0%
FY2019Dec 31, 2019$1.60M–
FY2018Dec 31, 2018$0–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$3.27M–
Q1 FY2026Mar 31, 2026$3.40M–
Q2 FY2025Jun 30, 2025$3.09M–
Q1 FY2025Mar 31, 2025$3.25M–

More OptimizeRx figures

See a number that looks wrong?